# Akari Therapeutics Plc: financial statements, quarterly

AKTX · Nasdaq · CIK 1541157 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aktx.md) · [Financials](/companies/aktx/financials.md) · [Filings](/companies/aktx/filings.md) · [Insiders](/companies/aktx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aktx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [(0.3)](/filings/0000950170-24-128727.md) | [2.5 d](/filings/0000950170-25-054278.md) | [2.3](/filings/0000950170-25-071563.md) | [3.3](/filings/0001641172-25-023569.md) | [0.1](/filings/0001493152-25-022390.md) | [1.2 d](/filings/0001493152-26-013664.md) | [0.8](/filings/0001493152-26-024446.md) | [0.7](/filings/0001493152-26-037730.md) | [0.2](/filings/0001493152-25-022390.md) | [1.1 d](/filings/0001493152-26-013664.md) | [1.5](/filings/0001493152-26-024446.md) | [2.1](/filings/0001493152-26-037730.md) |
| Selling, general and administrative | $m | [2.8](/filings/0000950170-24-128727.md) | [2.6 d](/filings/0000950170-25-054278.md) | [3.7](/filings/0000950170-25-071563.md) | [2.2](/filings/0001641172-25-023569.md) | [1.7](/filings/0001493152-25-022390.md) | [3.0 d](/filings/0001493152-26-013664.md) | [2.7](/filings/0001493152-26-024446.md) | [2.5](/filings/0001493152-26-037730.md) | [2.0](/filings/0001493152-25-022390.md) | [2.1 d](/filings/0001493152-26-013664.md) | [2.2](/filings/0001493152-26-024446.md) | [2.5](/filings/0001493152-26-037730.md) |
| Operating income | $m | [(2.5)](/filings/0000950170-24-128727.md) | [(5.1) d](/filings/0000950170-25-054278.md) | [(6.0)](/filings/0000950170-25-071563.md) | [(7.4)](/filings/0001641172-25-023569.md) | [(2.9)](/filings/0001493152-25-022390.md) | [(5.3) d](/filings/0001493152-26-013664.md) | [(3.5)](/filings/0001493152-26-024446.md) | [(3.1)](/filings/0001493152-26-037730.md) | [(7.4)](/filings/0001493152-25-022390.md) | [(3.2) d](/filings/0001493152-26-013664.md) | [(15.8)](/filings/0001493152-26-024446.md) | [(4.6)](/filings/0001493152-26-037730.md) |
| Interest expense | $m | not reported | not reported | not reported | [0.1](/filings/0000950170-24-098576.md) | [0.1](/filings/0001493152-25-022390.md) | [0.1 d](/filings/0001493152-26-013664.md) | [0.1](/filings/0001493152-26-024446.md) | [0.1](/filings/0001493152-26-037730.md) | [0.1](/filings/0001493152-25-022390.md) | [0.0 d](/filings/0001493152-26-013664.md) | [0.1](/filings/0001493152-26-024446.md) | [0.1](/filings/0001493152-26-037730.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0000950170-25-071563.md) | not reported | not reported | not reported | [0.0](/filings/0000950170-25-071563.md) | [0.0](/filings/0001641172-25-023569.md) | [(1.1)](/filings/0001493152-25-022390.md) | [0.1 d](/filings/0001493152-26-013664.md) | [(0.9)](/filings/0001493152-26-024446.md) | [0.0 d](/filings/0001493152-26-037730.md) |
| Net income | $m | [(2.9)](/filings/0000950170-24-128727.md) | [(4.1) d](/filings/0000950170-25-054278.md) | [(5.6)](/filings/0001493152-25-022390.md) | [(7.6)](/filings/0001493152-25-022390.md) | [(2.9)](/filings/0001493152-25-022390.md) | [(3.8) d](/filings/0001493152-26-013664.md) | [(3.7)](/filings/0001493152-26-037730.md) | [(1.9)](/filings/0001493152-26-037730.md) | [(6.4)](/filings/0001493152-25-022390.md) | [(5.3) d](/filings/0001493152-26-013664.md) | [(14.5)](/filings/0001493152-26-037730.md) | [(4.8)](/filings/0001493152-26-037730.md) |
| Diluted EPS | $ per share | [0.00](/filings/0000950170-24-128727.md) | not reported | [0.00](/filings/0000950170-25-071563.md) | [0.00](/filings/0001641172-25-023569.md) | [0.00](/filings/0001493152-25-022390.md) | not reported | [0.00](/filings/0001493152-26-024446.md) | [0.00](/filings/0001493152-26-037730.md) | [0.00](/filings/0001493152-25-022390.md) | not reported | [0.00](/filings/0001493152-26-024446.md) | [0.00](/filings/0001493152-26-037730.md) |
| Basic EPS | $ per share | [0.00](/filings/0000950170-24-128727.md) | not reported | [0.00](/filings/0000950170-25-071563.md) | [0.00](/filings/0001641172-25-023569.md) | [0.00](/filings/0001493152-25-022390.md) | not reported | [0.00](/filings/0001493152-26-024446.md) | [0.00](/filings/0001493152-26-037730.md) | [0.00](/filings/0001493152-25-022390.md) | not reported | [0.00](/filings/0001493152-26-024446.md) | [0.00](/filings/0001493152-26-037730.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | period not labelled (2024-02-29) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.8](/filings/0000950170-25-054278.md) | not reported | [1.3](/filings/0000950170-24-060556.md) | [4.2](/filings/0000950170-24-098576.md) | [2.2](/filings/0000950170-24-128727.md) | [0.0](/filings/0001493152-26-013664.md) | [2.6](/filings/0000950170-25-071563.md) | [2.7](/filings/0001641172-25-023569.md) | [2.5](/filings/0001493152-25-022390.md) | [5.2](/filings/0001493152-26-037730.md) | [2.8](/filings/0001493152-26-024446.md) | [7.7](/filings/0001493152-26-037730.md) |
| Current assets | $m | [4.3](/filings/0000950170-25-054278.md) | not reported | [2.8](/filings/0000950170-24-060556.md) | [5.1](/filings/0000950170-24-098576.md) | [2.7](/filings/0000950170-24-128727.md) | [3.0](/filings/0001493152-26-013664.md) | [3.3](/filings/0000950170-25-071563.md) | [3.3](/filings/0001641172-25-023569.md) | [2.9](/filings/0001493152-25-022390.md) | [5.5](/filings/0001493152-26-037730.md) | [3.6](/filings/0001493152-26-024446.md) | [8.3](/filings/0001493152-26-037730.md) |
| Total assets | $m | [4.4](/filings/0000950170-25-054278.md) | not reported | [2.8](/filings/0000950170-24-060556.md) | [5.1](/filings/0000950170-24-098576.md) | [2.7](/filings/0000950170-24-128727.md) | [50.6](/filings/0001493152-26-013664.md) | [51.0](/filings/0000950170-25-071563.md) | [50.9](/filings/0001641172-25-023569.md) | [45.4](/filings/0001493152-25-022390.md) | [47.9](/filings/0001493152-26-037730.md) | [33.9](/filings/0001493152-26-024446.md) | [38.6](/filings/0001493152-26-037730.md) |
| Current liabilities | $m | [4.6](/filings/0000950170-25-054278.md) | not reported | [6.3](/filings/0000950170-24-060556.md) | [8.8](/filings/0000950170-24-098576.md) | [9.4](/filings/0000950170-24-128727.md) | [19.9](/filings/0001493152-26-013664.md) | [20.9](/filings/0000950170-25-071563.md) | [17.1](/filings/0001641172-25-023569.md) | [15.6](/filings/0001493152-25-022390.md) | [12.4](/filings/0001493152-26-037730.md) | [13.4](/filings/0001493152-26-024446.md) | [13.9](/filings/0001493152-26-037730.md) |
| Total liabilities | $m | [4.6](/filings/0000950170-25-054278.md) | not reported | not reported | not reported | not reported | [28.3](/filings/0001493152-26-013664.md) | [29.2](/filings/0000950170-25-071563.md) | [25.3](/filings/0001641172-25-023569.md) | [22.7](/filings/0001493152-25-022390.md) | [19.6](/filings/0001493152-26-037730.md) | [19.5](/filings/0001493152-26-024446.md) | [20.0](/filings/0001493152-26-037730.md) |
| Short-term borrowings | $m | not reported | [1.1](/filings/0000950170-24-128727.md) | [0.9](/filings/0000950170-24-060556.md) | [0.6](/filings/0000950170-24-098576.md) | [0.2](/filings/0000950170-24-128727.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(0.2)](/filings/0001493152-26-013664.md) | not reported | [(3.6)](/filings/0001493152-25-022390.md) | [(3.7)](/filings/0001493152-25-022390.md) | [(6.7)](/filings/0001493152-25-022390.md) | [22.2](/filings/0001493152-26-037730.md) | [21.7](/filings/0001493152-26-037730.md) | [25.6](/filings/0001493152-26-037730.md) | [22.7](/filings/0001493152-25-022390.md) | [28.3](/filings/0001493152-26-037730.md) | [14.4](/filings/0001493152-26-037730.md) | [18.6](/filings/0001493152-26-037730.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,449) d](/filings/0000950170-24-128727.md) | [(4,409) d](/filings/0000950170-25-054278.md) | [(4,044)](/filings/0000950170-25-071563.md) | [(4,894) d](/filings/0001641172-25-023569.md) | [(1,490) d](/filings/0001493152-25-022390.md) | [(2,124) d](/filings/0001493152-26-013664.md) | [(2,150)](/filings/0001493152-26-024446.md) | [(3,256) d](/filings/0001493152-26-037730.md) | [(2,121) d](/filings/0001493152-25-022390.md) | [(3,041) d](/filings/0001493152-26-013664.md) | [(2,488)](/filings/0001493152-26-024446.md) | [(3,109) d](/filings/0001493152-26-037730.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q1 FY2016 (2016-03-31) | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | billions of shares | [1.2](/filings/0001144204-16-101257.md) | [7.6](/filings/0000950170-24-060556.md) | [10.1](/filings/0000950170-24-098576.md) | [10.1](/filings/0000950170-24-128727.md) | [13.5](/filings/0000950170-25-071563.md) | [18.8](/filings/0001641172-25-023569.md) | [24.4](/filings/0001493152-25-022390.md) | [54.6](/filings/0001493152-26-024446.md) | [62.9](/filings/0001493152-26-037730.md) | [65.3](/filings/0001493152-25-022390.md) | [119](/filings/0001493152-26-024446.md) | [143](/filings/0001493152-26-037730.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 155,758,529,533 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037730.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.